argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CEST.
All proposed resolutions on the agenda for this annual meeting were approved. The results of the votes will be posted shortly on the Company's website and are summarized below:
Changes to the board of directors
In the context of a further alignment of our governance model with international standards, Dr. J. de Koning, a non-executive director has resigned from the Board. Mr. Eric Castaldi also resigned as an executive director but remains the CFO of the Company. The shareholders have appointed Msc. A.A. Rosenberg as a new non-executive Director. Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis Pharma from January 2013 until February 2015. He has also been a Managing Director of MPM Capital, a venture capital firm, since April 2015 and currently serves as CEO of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing and mergers and acquisitions.
Peter Verhaeghe, chairman of the board, commented: "I would like to welcome Tony Rosenberg and to thank John de Koning for his long-lasting support to the company as venture capital investor and for his valuable strategic business and scientific contributions as a director. I am also pleased with the gradual transition of our board composition over the past years, with all non-executive directors qualifying now as independent directors."
Authorization to use shares in relation to a possible NASDAQ listing
Furthermore, the shareholders' meeting has granted the authorization to the board of directors to issue shares in relation to a possible NASDAQ listing of the Company in 2017.
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com